Sugi Predict

Sugi Predict / Compounds / SCHEMBL4184328

SCHEMBL4184328

SCHEMBL4184328

Cc1cc(Nc2nc(Cl)nc3sc(C)cc23)n[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLK4 O00444 3/20 0.61
▸ PAK4 O96013 3/20 0.61
▸ MEN1 O00255 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ AURKA O14965 13/20 0.44
▸ GSK3B P49841 7/20 0.43
▸ AURKB Q96GD4 7/20 0.43
▸ SRC P12931 5/20 0.43
▸ EIF2AK2 P19525 1/20 0.43
▸ GSK3A P49840 1/20 0.43
▸ NTRK1 P04629 3/20 0.42
▸ JAK2 O60674 2/20 0.42
▸ JAK3 P52333 2/20 0.42
▸ STK10 O94804 1/20 0.42
▸ RET P07949 1/20 0.42
▸ FGFR1 P11362 1/20 0.42
▸ FER P16591 1/20 0.42
▸ CSNK2A2 P19784 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24996468 0.81 PLK4 (0.63) PLK4PAK4MEN1HTTKMT2A
SCHEMBL22054231 0.81 PLK4 (0.60) PLK4PAK4MEN1HTTKMT2A
SCHEMBL4019999 0.79 PAK4 (0.54) PLK4PAK4MEN1HTTKMT2A
SCHEMBL30255484 0.78 MAPK1 (0.56) PLK4PAK4MEN1HTTKMT2A
SCHEMBL4176733 0.76 PLK4 (0.61) PLK4PAK4MEN1HTTKMT2A
SCHEMBL22054614 0.75 PAK4 (0.53) PLK4PAK4MEN1HTTKMT2A
SCHEMBL11204708 0.75 PDE2A (0.41) MEN1KMT2AFGFR1FLT3
SCHEMBL166340 0.75 NTRK1 (0.45) PLK4PAK4AURKAGSK3BAURKB
SCHEMBL785406 0.75 AURKA (0.70) PLK4PAK4AURKAGSK3BAURKB
SCHEMBL23889437 0.75 PLK4 (0.66) PLK4PAK4MEN1HTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116003441-B Heteroaromatic derivative regulator, preparation method and application thereof 江苏豪森药业集团有限公司 2025-06-10 — — CN disclosed
CN-115925705-B Heteroaromatic derivative regulator, preparation method and application thereof 江苏豪森药业集团有限公司 2024-12-31 — — CN disclosed
CN-116003441-A Heteroaromatic derivative regulator, preparation method and application thereof 江苏豪森药业集团有限公司 2023-04-25 — — CN disclosed
CN-115925705-A Heteroaromatic derivative regulator, preparation method and application thereof 江苏豪森药业集团有限公司 2023-04-07 — — CN disclosed
US-20230043863-A1 HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2023-02-09 — — US disclosed
US-20230043863-A1 HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2023-02-09 — — US disclosed
CN-115667228-A Salt and crystal form of heteroaromatic derivative and preparation method of salt and crystal form 上海翰森生物医药科技有限公司 2023-01-31 — — CN disclosed
CN-111511738-B Heteroaromatic derivative regulator, preparation method and application thereof 江苏豪森药业集团有限公司 2023-01-20 — — CN disclosed
WO-2021238908-A1 SALT AND CRYSTAL FORM OF HETEROARYL DERIVATIVE, AND PREPARATION METHOD THEREFOR 上海翰森生物医药科技有限公司 2021-12-02 — — WO disclosed
WO-2021238908-A1 SALT AND CRYSTAL FORM OF HETEROARYL DERIVATIVE, AND PREPARATION METHOD THEREFOR 上海翰森生物医药科技有限公司 2021-12-02 — — WO disclosed
EP-3889152-A1 HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2021-10-06 — — EP disclosed
EP-3889152-A1 HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) 2021-10-06 — — EP disclosed
WO-2020108613-A1 HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 江苏豪森药业集团有限公司 2020-06-04 — — WO disclosed
US-20090247554-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2009-10-01 — — US disclosed
US-20090247554-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2009-10-01 — — US disclosed
US-20090247554-A1 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2009-10-01 — — US disclosed
EP-1999135-A2 KINASE INHIBITORS Takeda San Diego, Inc. (US) 2008-12-10 — — EP disclosed
WO-2007117995-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-10-18 — — WO disclosed
WO-2007117995-A2 KINASE INHIBITORS TAKEDA SAN DIEGO, INC. (US) 2007-10-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247554-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K19 PLK4 290/4885PAK4 150/4885MEN1 1941/4885
US-20230043863-A1 HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF WEE2, WEE1, RORB PLK4 2282/4885PAK4 542/4885MEN1 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.